Oxol Drug Interactions

No pharmacokinetic interaction between 85 mg/m² of OXOL and infusional 5-FU has been observed in patients treated every 2 weeks, but increase of 5-FU plasma concentrations by approximately 20% have been observed with doses of 130 mg/m² of OXOL administered every 3 weeks. In vitro, platinum was not displaced from plasma proteins by the following medications: erythromycin, salicylate, sodium valproate, granisetron, and paclitaxel. In vitro, oxaliplatin is not metabolized by, nor does it inhibit, human cytochrome P450 isoenzymes. No P450-mediated drug-drug interactions are therefore anticipated in patients.
Since platinum-containing species are eliminated primarily through the kidney, clearance of these products may be decreased by co-administration of potentially nephrotoxic compounds, although this has not been specifically studied.
Avoid Concomitant Use: Avoid concomitant use of Oxaliplatin with any of the following: BCG (Intravesical); Deferiprone; Dipyrone; Natalizumab; Pimecrolimus; Tacrolimus (Topical); Vaccines (Live).
Increased Effect/Toxicity: Oxaliplatin may increase the levels/effects of: Clozapine; Deferiprone; Fingolimod; Leflunomide; Natalizumab; QTc-Prolonging Agents (Highest Risk); QTc-Prolonging Agents (Moderate Risk); Taxane Derivatives; Tofacitinib; Topotecan; Vaccines (Live).
The levels/effects of oxaliplatin may be increased by: Bupropion; Chloramphenicol (Ophthalmic); Denosumab; Dipyrone; Mifepristone; Ocrelizumab; Palifermin; Pimecrolimus; Promazine; Roflumilast; Tacrolimus (Topical); Trastuzumab.
Decreased Effect: Oxaliplatin may decreased the levels/effects of: BCG (Intravesical); Coccidioides immitis skin test; Fosphenytoin-Phenytoin; Lenograstim; Lipegfilgrastim; Nivolumab; Pidotimod; Sipuleucel-T, Tertomotide; Vaccines (Inactivated); Vaccines (Live).
The levels/effects of oxaliplatin may be decreased by: Echinacea.